130 related articles for article (PubMed ID: 12513914)
41. Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not.
Quinlivan EB; Zhang C; Stewart PW; Komoltri C; Davis MG; Wehbie RS
J Infect Dis; 2002 Jun; 185(12):1736-44. PubMed ID: 12085319
[TBL] [Abstract][Full Text] [Related]
42. Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma.
Gill PS; McLaughlin T; Espina BM; Tulpule A; Louie S; Lunardi-Iskandar Y; Gallo RC
J Natl Cancer Inst; 1997 Dec; 89(23):1797-802. PubMed ID: 9392621
[TBL] [Abstract][Full Text] [Related]
43. Induction of IL-6 gene expression in Kaposi's sarcoma cells.
Yang J; Hagan MK; Offermann MK
J Immunol; 1994 Jan; 152(2):943-55. PubMed ID: 8283061
[TBL] [Abstract][Full Text] [Related]
44. A phase II study of liposomal doxorubicin in the treatment of HIV-related Kaposi's sarcoma.
Newell M; Milliken S; Goldstein D; Lewis C; Boyle M; Dolan G; Ryan S; Cooper DA
Aust N Z J Med; 1998 Dec; 28(6):777-83. PubMed ID: 9972406
[TBL] [Abstract][Full Text] [Related]
45. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma.
Bailey J; Pluda JM; Foli A; Saville MW; Bauza S; Adamson PC; Murphy RF; Cohen RB; Broder S; Yarchoan R
J Clin Oncol; 1995 Aug; 13(8):1966-74. PubMed ID: 7636537
[TBL] [Abstract][Full Text] [Related]
46. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma.
Gill PS; Lunardi-Ishkandar Y; Louie S; Tulpule A; Zheng T; Espina BM; Besnier JM; Hermans P; Levine AM; Bryant JL; Gallo RC
N Engl J Med; 1996 Oct; 335(17):1261-9. PubMed ID: 8857005
[TBL] [Abstract][Full Text] [Related]
47. High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma.
Frissen PH; de Wolf F; Reiss P; Bakker PJ; Veenhof CH; Danner SA; Goudsmit J; Lange JM
J Infect Dis; 1997 Sep; 176(3):811-4. PubMed ID: 9291341
[TBL] [Abstract][Full Text] [Related]
48. Endogenous basic fibroblast growth factor is essential for cyclin E-CDK2 activity in multiple external cytokine-induced proliferation of AIDS-associated Kaposi's sarcoma cells: dual control of AIDS-associated Kaposi's sarcoma cell growth and cyclin E-CDK2 activity by endogenous and external signals.
Murakami-Mori K; Mori S; Nakamura S
J Immunol; 1998 Aug; 161(4):1694-704. PubMed ID: 9712033
[TBL] [Abstract][Full Text] [Related]
49. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.
Tulpule A; Groopman J; Saville MW; Harrington W; Friedman-Kien A; Espina BM; Garces C; Mantelle L; Mettinger K; Scadden DT; Gill PS
Cancer; 2002 Jul; 95(1):147-54. PubMed ID: 12115328
[TBL] [Abstract][Full Text] [Related]
50. Activity of thalidomide in AIDS-related Kaposi's sarcoma.
Little RF; Wyvill KM; Pluda JM; Welles L; Marshall V; Figg WD; Newcomb FM; Tosato G; Feigal E; Steinberg SM; Whitby D; Goedert JJ; Yarchoan R
J Clin Oncol; 2000 Jul; 18(13):2593-602. PubMed ID: 10893291
[TBL] [Abstract][Full Text] [Related]
51. Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial.
Pourcher V; Desnoyer A; Assoumou L; Lebbe C; Curjol A; Marcelin AG; Cardon F; Gibowski S; Salmon D; Chennebault JM; Poizot-Martin I; Peytavin G; Boué F; Costagliola D
AIDS Res Hum Retroviruses; 2017 Jan; 33(1):1-10. PubMed ID: 27405442
[TBL] [Abstract][Full Text] [Related]
52. [Immune activation in AIDS related Kaposi's sarcoma].
Zhu B; Wu NP; Hoxtermann S; Bader A; Brockmeyer N
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 32(2):101-3. PubMed ID: 12734931
[TBL] [Abstract][Full Text] [Related]
53. Pilot Trial AMC-063: Safety and Efficacy of Bortezomib in AIDS-associated Kaposi Sarcoma.
Reid EG; Suazo A; Lensing SY; Dittmer DP; Ambinder RF; Maldarelli F; Gorelick RJ; Aboulafia D; Mitsuyasu R; Dickson MA; Wachsman W;
Clin Cancer Res; 2020 Feb; 26(3):558-565. PubMed ID: 31624104
[TBL] [Abstract][Full Text] [Related]
54. In vivo effects of interleukin 3 in HIV type 1-infected patients with cytopenia.
Scadden DT; Levine JD; Bresnahan J; Gere J; McGrath J; Wang Z; Resta DJ; Young D; Hammer SM
AIDS Res Hum Retroviruses; 1995 Jun; 11(6):731-40. PubMed ID: 7576933
[TBL] [Abstract][Full Text] [Related]
55. Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial.
Krown SE; Lee JY; Lin L; Fischl MA; Ambinder R; Von Roenn JH
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):149-53. PubMed ID: 16394845
[TBL] [Abstract][Full Text] [Related]
56. Fatal pulmonary Kaposi sarcoma in an HIV seronegative AIDS patient.
Zhang H; Wang HL; Zhong DR; Liu Y; Li NN; Zhang W; Xiao Y; Li TS
Clin Respir J; 2017 Nov; 11(6):1040-1044. PubMed ID: 26861193
[TBL] [Abstract][Full Text] [Related]
57. Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients.
Takebe N; Paredes J; Pino MC; Lownsbury WH; Agosti J; Krown SE
J Interferon Cytokine Res; 1998 May; 18(5):321-6. PubMed ID: 9620359
[TBL] [Abstract][Full Text] [Related]
58. A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.
Uldrick TS; Gonçalves PH; Wyvill KM; Peer CJ; Bernstein W; Aleman K; Polizzotto MN; Venzon D; Steinberg SM; Marshall V; Whitby D; Little RF; Wright JJ; Rudek MA; Figg WD; Yarchoan R
Oncologist; 2017 May; 22(5):505-e49. PubMed ID: 28341759
[TBL] [Abstract][Full Text] [Related]
59. Outcome markers of ART-treated HIV+ patients with early stage Kaposi's sarcoma.
Ngalamika O; Tso FY; Lidenge S; Munsaka S; Shea D; Wood C; West J
PLoS One; 2020; 15(7):e0235865. PubMed ID: 32634155
[TBL] [Abstract][Full Text] [Related]
60. Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study.
Krischer J; Rutschmann O; Hirschel B; Vollenweider-Roten S; Saurat JH; Pechère M
J Am Acad Dermatol; 1998 Apr; 38(4):594-8. PubMed ID: 9555800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
